198 related articles for article (PubMed ID: 34096050)
41. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
Moriarty B; Whittaker S
Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
[TBL] [Abstract][Full Text] [Related]
42. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
43. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.
Whittaker SJ; Marsden JR; Spittle M; Russell Jones R; ;
Br J Dermatol; 2003 Dec; 149(6):1095-1107. PubMed ID: 14696593
[No Abstract] [Full Text] [Related]
44. Classification of primary cutaneous T-cell lymphomas.
Willemze R; Beljaards RC; Meijer CJ
Histopathology; 1994 May; 24(5):405-15. PubMed ID: 8088712
[TBL] [Abstract][Full Text] [Related]
45. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
46. [Diagnostics of primary cutaneous lymphomas].
Felcht M; Hillen U; Klemke CD
Hautarzt; 2017 Sep; 68(9):696-701. PubMed ID: 28779267
[TBL] [Abstract][Full Text] [Related]
47. [Diagnosis of malignant cutaneous lymphomas].
Sterry W
Dtsch Med Wochenschr; 1988 Feb; 113(5):184-9. PubMed ID: 3276493
[No Abstract] [Full Text] [Related]
48. New techniques in the evaluation of cutaneous T-cell lymphoma.
van Vloten WA; Willemze R
Dermatol Clin; 1985 Oct; 3(4):665-72. PubMed ID: 3916173
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous T-cell lymphoma and atopy: is there an association?
Mehrany K; El-Azhary RA; Bouwhuis SA; Pittelkow MR
Br J Dermatol; 2003 Nov; 149(5):1013-7. PubMed ID: 14632807
[TBL] [Abstract][Full Text] [Related]
50. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
51. Manifestations of cutaneous T-cell lymphoma.
Carney DN; Bunn PA
J Dermatol Surg Oncol; 1980 May; 6(5):369-77. PubMed ID: 6966639
[No Abstract] [Full Text] [Related]
52. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
53. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
54. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
[TBL] [Abstract][Full Text] [Related]
55. Letter to the editor with regard to the article entitled "Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping".
Roelens M; de Masson A; Ram-Wolff C; Bagot M; Moins-Teisserenc H
Cytometry B Clin Cytom; 2021 Mar; 100(2):139-140. PubMed ID: 33031631
[No Abstract] [Full Text] [Related]
56. Unmasking mycosis fungoides/Sézary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course.
Foo SH; Shah F; Chaganti S; Stevens A; Scarisbrick JJ
Br J Dermatol; 2016 Apr; 174(4):901-4. PubMed ID: 26479768
[No Abstract] [Full Text] [Related]
57. Authors reply to the letter to editor with regard to the article titled "Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping".
Almeida J; Pulitzer MP; Horna P
Cytometry B Clin Cytom; 2021 Mar; 100(2):141. PubMed ID: 33166040
[No Abstract] [Full Text] [Related]
58. Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Lemchak D; Banerjee S; Digambar SS; Hood BL; Conrads TP; Jedrych J; Geskin L; Akilov OE
Exp Dermatol; 2018 Feb; 27(2):188-190. PubMed ID: 29205518
[TBL] [Abstract][Full Text] [Related]
59. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
60. Lymph node histopathology in mycosis fungoides and Sézary's syndrome.
Scheffer E; Meijer CJ; Willemze R; van Vloten WA
Curr Probl Dermatol; 1990; 19():105-13. PubMed ID: 2404671
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
